MediWound to Report Fourth Quarter and Full Year 2025 Financial Results
MediWound (Nasdaq: MDWD) will report its fourth quarter and full year 2025 financial results on Thursday, March 5, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MediWound (Nasdaq: MDWD) will report its fourth quarter and full year 2025 financial results on Thursday, March 5, 2026. Management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss results and business highlights.
Dial-in numbers and a live webcast link are provided, and an archived replay will be available on the company's Investors website.
Details
News Market Reaction – MDWD
On Feb 19, the day this news came out, MDWD closed 0.88% above the previous close.
Data tracked by StockTitan Argus for the Feb 19 session.
Key Figures
- Earnings release date
- March 5, 2026
- Scheduled report of Q4 and full-year 2025 results
- Conference call time
- 8:30 a.m. Eastern Time
- Start time for earnings call and webcast
- Dial-in lead time
- 5 minutes
- Participants asked to dial in before call start
- Toll-free number
- 1-844-676-8833
- Primary U.S. access number for the earnings call
Historical Context
-
Upcoming presentations at major healthcare investor conferences with webcasts.
-
Corporate update with clinical progress and multi‑year revenue guidance.
-
New clinical data showing NexoBrid effectiveness in preventing traumatic tattoos.
-
Q3 2025 results with revenue growth, facility expansion, and equity financing.
-
Announcement of Q3 2025 results date and related conference call details.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MediWound to Report Fourth Quarter and Full Year 2025 Financial Results
Conference Call and Webcast Scheduled for Thursday, March 5th at 8:30 a.m. Eastern Time
YAVNE, Israel, February 19, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, March 5, 2026.
Following the release, MediWound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide business highlights.
Conference Call & Webcast Details
Toll-Free: 1-844-676-8833
Israel: 1-80-921-2373
International: 1-412-634-6869
Webcast: Click HERE
To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay on the Investors section of the MediWound website.
About MediWound
MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company pioneering enzymatic, non-surgical therapies for tissue repair. The company’s FDA-approved biologic, NexoBrid®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the United States, European Union, Japan, and additional international markets. MediWound’s late-stage pipeline product, EscharEx®, is an investigational therapy for the debridement of chronic wounds, with potential to become a new standard of care in wound management.
For more information, visit www.mediwound.com and follow us on LinkedIn and X (formerly Twitter).
MediWound Contacts:
Hani Luxenburg Daniel Ferry
Chief Financial Officer Managing Director
MediWound Ltd. LifeSci Advisors, LLC
ir@mediwound.com daniel@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.